查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2024219

真實世界數據市場規模、佔有率和趨勢分析：按來源、應用、最終用戶和地區分類 - 全球機會分析和行業預測

Real-World Data Market Size, Share & Trends Analysis by Source, Application, End User, and Geography - Global Opportunity Analysis and Industry Forecast
出版日期: | 出版商: Meticulous Research | 英文 170 Pages | 訂單完成後即時交付

價格

全球真實世界數據（RWD）市場預計將從2026年的13.3億美元成長至2036年的24.3億美元，預計在2026年至2036年的預測期內，複合年成長率將達到6.4%。本報告對全球真實世界數據市場在五個主要區域的市場狀況進行了詳細分析，重點關注當前市場趨勢、市場規模、近期發展以及2036年的預測。

本報告基於廣泛的一手和二手研究，以及對市場情景的詳細分析，對關鍵產業促進因素、限制因素、機會和挑戰進行了影響分析。推動市場成長的因素包括：全球醫療產業向價值醫療模式的轉變；對真實世界證據（RWE）的需求不斷成長，以支持報銷和保險覆蓋決策；對加快藥物研發進度和降低研發成本的需求日益成長；監管機構（如美國FDA和EMA）對RWE申請的接受度不斷提高；以及全球醫療保健系統的快速數位化。此外，巨量資料分析和人工智慧（AI）技術的進步，使得從複雜的真實世界數據（RWD）資料集中獲得更深入的洞察成為可能；電子健康記錄（EHR）的普及和互通性；以及透過穿戴式裝置和行動應用程式開展的分散式臨床試驗和以患者為中心的數據收集的擴展，預計也將促進市場成長。然而，對病患資料隱私和安全的擔憂、嚴格的資料管治和監管合規要求，以及與分散的醫療保健系統之間的資料標準化、品質和互通性相關的挑戰，可能會抑制市場成長。

全球真實世界數據市場按數據來源（電子病歷/電子健康記錄/臨床數據、計費數據、臨床試驗數據、藥房數據、患者生成數據/穿戴式設備數據）、應用領域（藥物研發與核准、市場進入與報銷、上市後監測、醫療設備評估及其他應用）、最終用戶（製藥、生物技術和醫療設備及其他地區支付方、醫療設備及其他地區進行用戶細分服務公司。本研究評估了行業競爭對手，並提供了國家層面的市場分析。

目錄

  • 目錄

第1章：引言

第2章：調查方法

第3章執行摘要

第4章 市場洞察

  • 全球真實世界數據市場促進因素：影響分析（2026-2036 年）
    • 向價值驅動型醫療保健的轉變和藥物研發成本的上升
    • 監管機構對真實世界證據的接受度提高
    • 巨量資料在醫療領域的應用日益廣泛
  • 市場限制因素
    • 資料隱私和安全問題
    • 缺乏數據標準化和互通性
  • 市場機遇
    • 個人化醫療以及治療需求尚未滿足的領域
    • 人工智慧與進階分析的融合
  • 市場挑戰
    • 與數據品質和完整性相關的挑戰
    • 應對複雜的監理局面
  • 市場趨勢
    • 擴大分散式和以患者為中心的資料收集
    • 患者產生的健康數據的重要性日益凸顯
  • 波特五力分析

第5章：全球真實世界資料市場：依來源分類

  • 電子病歷/電子健康紀錄/臨床數據
  • 帳單和收費數據
  • 藥房數據
  • 產品和疾病登記數據
  • 基因組數據
  • 患者產生的數據/穿戴式裝置數據
  • 其他來源

第6章：全球真實世界數據市場：依應用領域分類

  • 市場准入和贖回/付款方的決策
  • 藥物研發及核准
  • 上市後監測
  • 醫療設備的研發與核准
  • 臨床和監管決策

第7章：全球真實世界數據市場：依最終用戶分類

  • 製藥、生技和醫療設備公司
  • 健康保險提供者
  • 醫療服務提供方
  • 其他最終用戶

第8章：真實世界數據市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
  • 中東和非洲

第9章 競爭情勢

  • 競爭性標竿分析
  • 競爭對手儀錶板
    • 產業領導者
    • 市場差異化因素
    • 先鋒公司
    • 新興企業
  • 市場佔有率和定位分析

第10章：公司簡介

  • Iqvia Holdings Inc.
  • Ppd Inc.（Subsidiary of Thermo Fisher Scientific Inc.）
  • Merative
  • Unitedhealth Group Incorporated（Optum）
  • Icon Plc
  • Syneos Health, Inc.
  • Aetion, Inc.
  • Flatiron Health, Inc.
  • Verana Health
  • Oracle Corporation
  • Sas Institute Inc.
  • Parexel International Corporation
  • Elevance Health, Inc.

第11章附錄

Product Code: MRHC - 104611

Real-World Data (RWD) Market by Source, Application (Drug Development, Market Access), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036

According to the research report titled, 'Real-World Data (RWD) Market by Source (EHR, Claims, Clinical Trials, Pharmacy, Patient-Reported), Application (Drug Development, Market Access, Post-Market Surveillance), End User (Pharma & Biotech, Payers, Providers), and Geography - Global Forecast to 2036' the global real-world data (RWD) market is expected to reach USD 2.43 billion by 2036 from USD 1.33 billion in 2026, growing at a CAGR of 6.4% during the forecast period 2026 to 2036. The report provides an in-depth analysis of the global real-world data market across five major regions, emphasizing the current market trends, market sizes, recent developments, and forecasts till 2036.

Succeeding extensive secondary and primary research and an in-depth analysis of the market scenario, the report conducts the impact analysis of the key industry drivers, restraints, opportunities, and challenges. The growth of this market is driven by the global healthcare industry's shift toward value-based care and increasing demand for real-world evidence (RWE) to support reimbursement and coverage decisions, the rising need to accelerate drug development timelines and reduce R&D costs, increasing regulatory acceptance of RWE for submissions to agencies such as the U.S. FDA and the EMA, and the rapid digitalization of healthcare systems globally. Moreover, advancements in big data analytics and artificial intelligence enabling deeper insights from complex RWD datasets, the proliferation of electronic health records (EHRs) and their growing interoperability, and the expansion of decentralized clinical trials and patient-centric data collection through wearables and mobile apps are expected to support the market's growth. However, concerns around patient data privacy and security, stringent data governance and regulatory compliance requirements, and challenges related to data standardization, quality, and interoperability across fragmented healthcare systems may restrain market growth.

The key players operating in the global real-world data market are IQVIA Inc. (U.S.), Merative (U.S.), Optum Inc. (U.S.), ICON plc (Ireland), Syneos Health (U.S.), Aetion, Inc. (U.S.), Flatiron Health, Inc. (U.S.), Verana Health (U.S.), Oracle Corporation (U.S.), SAS Institute Inc. (U.S.), Parexel International Corporation (U.S.), and Elevance Health, Inc. (U.S.), among others.

The global real-world data market is segmented by source (EMR/EHR/clinical data, claims data, clinical trials data, pharmacy data, and patient-generated/wearable data), application (drug development & approvals, market access & reimbursement, post-market surveillance, medical device evaluation, and other applications), end user (pharmaceutical, biotechnology & medical device companies; payers; providers; and other end users), and geography. The study also evaluates industry competitors and analyzes the market at the country level.

Based on source, the EMR/EHR/Clinical Data segment is expected to account for the largest share of the global real-world data market in 2026. The segment accounts for approximately 45-50% of the overall real-world data market in 2026, reflecting the widespread and growing adoption of electronic health record systems across healthcare settings globally. EHRs represent the richest and most comprehensive source of longitudinal patient data, containing detailed clinical information including diagnoses, medications, laboratory results, imaging reports, and physician notes that provide deep insight into individual patient care journeys and treatment outcomes over time. The increasing interoperability of EHR systems, driven by regulatory mandates such as the U.S. 21st Century Cures Act and the adoption of standardized data models including the OMOP Common Data Model, is enhancing the analytical utility of this data source for large-scale retrospective studies, observational research, and regulatory submissions. Healthcare systems in North America and Europe in particular have achieved high EHR adoption rates, providing a mature and continuously growing repository of real-world clinical data that underpins pharmaceutical research, health technology assessment, and outcomes-based contracting.

However, the Patient-Generated/Wearable Data segment is expected to register the fastest growth during the forecast period, driven by the rapid proliferation of consumer wearables, biosensors, remote monitoring devices, and digital health applications that continuously capture physiological, behavioral, and patient-reported health data outside traditional care settings. The acceleration of decentralized clinical trials and the growing regulatory acceptance of digital health data for clinical research are further expanding the role of patient-generated data as a complementary and increasingly valuable source of real-world evidence.

Based on application, the Drug Development & Approvals segment is expected to account for the largest share of the global real-world data market in 2026. The segment holds approximately 35-40% of total real-world data market revenue in 2026, reflecting the central and expanding role of RWD across the entire pharmaceutical product lifecycle. Pharmaceutical and biotechnology companies leverage RWD at multiple stages of drug development: informing clinical trial design by modeling disease progression and identifying appropriate patient cohorts; creating external and synthetic control arms for single-arm trials in oncology and rare diseases, which can substantially compress development timelines; and generating supplementary post-approval safety and effectiveness evidence for regulatory submissions. Regulatory agencies including the U.S. FDA and the European Medicines Agency are progressively expanding their frameworks for accepting RWE to support new indications, labeling modifications, and pharmacovigilance obligations, providing a strong institutional driver for continued investment in RWD-based drug development programs. The convergence of RWD with AI-powered analytics platforms is further accelerating drug discovery and translational research by enabling the identification of novel biomarkers and the prediction of patient subgroup responses at scale.

The Market Access & Reimbursement and Post-Market Surveillance applications are also witnessing steady growth, driven by increasing pressure from payers and health technology assessment bodies for evidence of real-world clinical and economic value, as well as mandatory post-approval safety monitoring obligations for approved therapies.

Based on end user, the Pharmaceutical, Biotechnology & Medical Device Companies segment is expected to account for the largest share of the global real-world data market in 2026, and is also projected to register the fastest CAGR during the forecast period. Pharmaceutical, biotechnology, and medical device companies represent the dominant end-user segment in the global real-world data market, as these organizations are the primary generators of demand for RWD assets and analytics capabilities across clinical development, regulatory strategy, health economics, and commercial functions. The growing complexity of modern drug development programs, including the rise of precision oncology, gene and cell therapies, and rare disease treatments, is intensifying reliance on RWD to complement or supplement traditional randomized controlled trial evidence where standard trial designs are logistically or ethically infeasible. The integration of RWD into early pipeline decisions, competitive intelligence, patient identification, and commercial launch strategy is further broadening its use beyond the regulatory domain. The segment's fastest-growth projection is underpinned by the increasing volume of new molecular entities entering development, the expansion of real-world evidence requirements from global health authorities, and the growing adoption of AI-enabled RWD platforms that enable sponsors to extract higher-value insights from existing data assets.

A thorough geographic analysis of the industry gives detailed insights into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to account for the largest share of the global real-world data market in 2026. North America's dominant position is primarily attributed to its highly advanced healthcare IT infrastructure, the high adoption rate of interoperable electronic health records, and a favorable and increasingly explicit regulatory environment for the use of RWE. The U.S. FDA's RWE program, established under the 21st Century Cures Act, has provided a clear and progressively expanding framework for the submission and acceptance of real-world evidence in regulatory decisions, encouraging substantial investment and innovation from pharmaceutical sponsors and RWD solution providers. The region hosts a large, well-established ecosystem of RWD vendors, analytics technology companies, academic research institutions, and clinical research organizations with significant RWE capabilities, providing a dense competitive environment that drives continuous advancement in data quality and analytical methodology. The presence of large integrated health systems with longitudinal patient data assets, along with active participation of major payers in outcomes-based contracting arrangements that depend on RWD, further reinforces North America's market leadership.

However, Asia Pacific is expected to witness the fastest CAGR during the forecast period, driven by massive government investments in healthcare digitalization in countries including China, Japan, India, and Singapore, a rapidly expanding pharmaceutical market and clinical trial landscape, and the progressive maturation of data infrastructure and regulatory frameworks for the use of health data in research. The region's large and diverse patient population also makes it an increasingly important source of real-world data for global drug development programs seeking to demonstrate efficacy and safety across varied ethnic and demographic groups.

Europe is the second-largest regional market, supported by landmark initiatives including the European Health Data Space (EHDS) and the EMA's DARWIN EU network, which are designed to facilitate cross-border access to harmonized health data for research and regulatory purposes. While navigating the complexities of GDPR compliance remains a continuing challenge, the strong institutional push for data-driven healthcare across EU member states is creating significant structural demand for RWD solutions and analytics capabilities.

Key Questions Answered in the Report-

  • How big is the global real-world data market, and at what CAGR is this market projected to grow during 2026-2036?
  • What are the historical market sizes and growth rates of the global real-world data market?
  • What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
  • Which segments in terms of source, application, and end user are expected to create major traction for the manufacturers in this market?
  • Which source segment is expected to hold the major share, and which source segment is projected to register the fastest CAGR during the forecast period?
  • How are AI and advanced analytics transforming real-world data capabilities and the value of real-world evidence generation?
  • What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the global real-world data market?
  • Who are the major players in the global real-world data market? What are their specific product/service offerings in this market?
  • What are the recent strategic developments in the global real-world data market? What are the impacts of these strategic developments on the market?

Scope of the Report:

Real-World Data Market Assessment - by Source

  • EMR/EHR/Clinical Data
  • Claims Data
    • Medical Claims
    • Pharmacy Claims
  • Clinical Trials Data
  • Pharmacy Data
  • Patient-Generated/Wearable Data
    • Patient-Reported Outcomes (PROs)
    • Wearable & Remote Monitoring Device Data
    • Mobile Health (mHealth) App Data
  • Other Sources
    • Disease Registries
    • Biobank Data

Real-World Data Market Assessment - by Application

  • Drug Development & Approvals
  • Market Access & Reimbursement
  • Post-Market Surveillance
  • Medical Device Evaluation
  • Other Applications

Real-World Data Market Assessment - by End User

  • Pharmaceutical, Biotechnology & Medical Device Companies
  • Payers
  • Providers
    • Hospitals & Health Systems
    • Clinics & Physician Groups
  • Other End Users
    • Academic & Research Institutions
    • Contract Research Organizations (CROs)
    • Government & Regulatory Bodies

Real-World Data Market Assessment - by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Singapore
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • Israel
    • Saudi Arabia
    • UAE
    • Rest of Middle East & Africa

TABLE OF CONTENTS

  • Table of Contents

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Currency & Limitations

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research
  • 2.3. Market Assessment
    • 2.3.1. Market Size Estimation
    • 2.3.2. Bottom-Up Approach
    • 2.3.3. Top-Down Approach
    • 2.3.4. Growth Forecast
  • 2.4. Assumptions For The Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Global Real-World Data Market Drivers: Impact Analysis (2026-2036)
    • 4.2.1. Shift Toward Value-Based Care and Rising Drug Development Costs
    • 4.2.2. Increasing Regulatory Acceptance of Real-World Evidence
    • 4.2.3. Growing Adoption of Big Data In Healthcare
  • 4.3. Global Real-World Data Market: Impact Analysis of Market Restraints (2026-2036)
    • 4.3.1. Data Privacy and Security Concerns
    • 4.3.2. Lack of Data Standardization and Interoperability
  • 4.4. Global Real-World Data Market: Impact Analysis of Market Opportunities (2026-2036)
    • 4.4.1. Personalized Medicine and Underserved Therapeutic Areas
    • 4.4.2. Integration of Ai and Advanced Analytics
  • 4.5. Global Real-World Data Market: Impact Analysis of Market Challenges (2026-2036)
    • 4.5.1. Data Quality and Completeness Issues
    • 4.5.2. Navigating Complex Regulatory Landscapes
  • 4.6. Global Real-World Data Market: Impact Analysis of Market Trends (2026-2036)
    • 4.6.1. Expansion of Decentralized and Patient-Centric Data Collection
    • 4.6.2. Growing Importance of Patient-Generated Health Data
  • 4.7. Porter's Five Forces Analysis
    • 4.7.1. Threat of New Entrants
    • 4.7.2. Bargaining Power of Suppliers
    • 4.7.3. Bargaining Power of Buyers
    • 4.7.4. Threat of Substitute Products
    • 4.7.5. Competitive Rivalry

5. Global Real-World Data Market, By Source

  • 5.1. Overview
  • 5.2. Emr/Ehr/Clinical Data
  • 5.3. Claims & Billing Data
  • 5.4. Pharmacy Data
  • 5.5. Product/Disease Registries Data
  • 5.6. Genomics Data
  • 5.7. Patient-Generated/Wearable Data
  • 5.8. Other Sources

6. Global Real-World Data Market, By Application

  • 6.1. Overview
  • 6.2. Market Access & Reimbursement/Payer Decisions
  • 6.3. Drug Development & Approvals
  • 6.4. Post-Market Surveillance
  • 6.5. Medical Device Development & Approvals
  • 6.6. Clinical & Regulatory Decision-Making

7. Global Real-World Data Market, By End User

  • 7.1. Overview
  • 7.2. Pharmaceutical, Biotechnology, and Medical Device Companies
  • 7.3. Healthcare Payers
  • 7.4. Healthcare Providers
  • 7.5. Other End Users

8. Real-World Data Market, By Geography

  • 8.1. Overview
  • 8.2. North America
    • 8.2.1. U.S.
    • 8.2.2. Canada
  • 8.3. Europe
    • 8.3.1. Germany
    • 8.3.2. U.K.
    • 8.3.3. France
    • 8.3.4. Italy
    • 8.3.5. Spain
    • 8.3.6. Rest of Europe
  • 8.4. Asia-Pacific
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Rest of Asia-Pacific
  • 8.5. Latin America
  • 8.6. Middle East & Africa

9. Competitive Landscape

  • 9.1. Introduction
  • 9.2. Competitive Benchmarking
  • 9.3. Competitive Dashboard
    • 9.3.1. Industry Leaders
    • 9.3.2. Market Differentiators
    • 9.3.3. Vanguards
    • 9.3.4. Emerging Companies
  • 9.4. Market Share/Position Analysis

10. Company Profiles

  • 10.1. Iqvia Holdings Inc.
    • 10.1.1. Company Overview
    • 10.1.2. Financial Overview
    • 10.1.3. Product Portfolio
    • 10.1.4. Strategic Developments
    • 10.1.5. Swot Analysis
  • 10.2. Ppd Inc. (Subsidiary of Thermo Fisher Scientific Inc.)
    • 10.2.1. Company Overview
    • 10.2.2. Financial Overview
    • 10.2.3. Product Portfolio
    • 10.2.4. Strategic Developments
    • 10.2.5. Swot Analysis
  • 10.3. Merative
    • 10.3.1. Company Overview
    • 10.3.2. Product Portfolio
    • 10.3.3. Swot Analysis
  • 10.4. Unitedhealth Group Incorporated (Optum)
    • 10.4.1. Company Overview
    • 10.4.2. Financial Overview
    • 10.4.3. Product Portfolio
    • 10.4.4. Strategic Developments
    • 10.4.5. Swot Analysis
  • 10.5. Icon Plc
    • 10.5.1. Company Overview
    • 10.5.2. Financial Overview
    • 10.5.3. Product Portfolio
    • 10.5.4. Strategic Developments
    • 10.5.5. Swot Analysis
  • 10.6. Syneos Health, Inc.
    • 10.6.1. Company Overview
    • 10.6.2. Product Portfolio
    • 10.6.3. Swot Analysis
  • 10.7. Aetion, Inc.
    • 10.7.1. Company Overview
    • 10.7.2. Product Portfolio
    • 10.7.3. Strategic Developments
    • 10.7.4. Swot Analysis
  • 10.8. Flatiron Health, Inc.
    • 10.8.1. Company Overview
    • 10.8.2. Product Portfolio
    • 10.8.3. Strategic Developments
    • 10.8.4. Swot Analysis
  • 10.9. Verana Health
    • 10.9.1. Company Overview
    • 10.9.2. Product Portfolio
    • 10.9.3. Strategic Developments
    • 10.9.4. Swot Analysis
  • 10.10. Oracle Corporation
    • 10.10.1. Company Overview
    • 10.10.2. Financial Overview
    • 10.10.3. Product Portfolio
    • 10.10.4. Strategic Developments
    • 10.10.5. Swot Analysis
  • 10.11. Sas Institute Inc.
    • 10.11.1. Company Overview
    • 10.11.2. Product Portfolio
    • 10.11.3. Swot Analysis
  • 10.12. Parexel International Corporation
    • 10.12.1. Company Overview
    • 10.12.2. Product Portfolio
    • 10.12.3. Swot Analysis
  • 10.13. Elevance Health, Inc.
    • 10.13.1. Company Overview
    • 10.13.2. Financial Overview
    • 10.13.3. Product Portfolio
    • 10.13.4. Swot Analysis

11. Appendix

  • 11.1. Available Customization
  • 11.2. Related Reports

LIST OF TABLES

LIST OF TABLES

  • Table 1. Global Real-World Data Market Drivers: Impact Analysis (2026-2036)
  • Table 2. Key Global Regulatory Milestones for RWE Acceptance (2016-2025)
  • Table 3. Global Real-World Data Market Restraints: Impact Analysis (2026-2036)
  • Table 4. Global Real-World Data Market Opportunities: Impact Analysis (2026-2036)
  • Table 5. Global Real-World Data Market Challenges: Impact Analysis (2026-2036)
  • Table 6. Global Real-World Data Market Trends: Impact Analysis (2026-2036)
  • Table 7. Global Real-World Data Market - Porter's Five Forces Summary (2025-2026)
  • Table 8. Global Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 9. Global Real-World Data Market, By Source - Overview (2026)
  • Table 10. Global Real-World Data Market Size for Emr/Ehr/Clinical Data, By Country/Region, 2024-2036 (USD Million)
  • Table 11. Global Real-World Data Market Size for Claims & Billing Data, By Country/Region, 2024-2036 (USD Million)
  • Table 12. U.S. E-Prescription Volume, 2019-2024 (In Billion)
  • Table 13. Global Real-World Data Market Size for Pharmacy Data, By Country/Region, 2024-2036 (USD Million)
  • Table 14. Selected Global Disease & Product Registries (2025)
  • Table 15. Global Real-World Data Market Size for Product/Disease Registries Data, By Country/Region, 2024-2036 (USD Million)
  • Table 16. Major Global Genomics Biobanks and Cohort Studies (2025)
  • Table 17. Global Real-World Data Market Size for Genomic Data, By Country/Region, 2024-2036 (USD Million)
  • Table 18. Global Wearable Device Shipments and Health Adoption Trends, 2022-2025
  • Table 19. Selected FDA-Cleared Wearable Devices Generating RWD (2018-2024)
  • Table 20. Global Real-World Data Market Size for Patient Generated/Wearable Data, By Country/Region, 2024-2036 (USD Million)
  • Table 21. Global Real-World Data Market Size for Other Data Sources, By Country/Region, 2024-2036 (USD Million)
  • Table 22. Global Real-World Data Market, By Application - Overview (2026)
  • Table 23. Global Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 24. U.S. Medicare Drug Price Negotiation Program - RWD Relevance (Ira, 2026-2029+)
  • Table 25. Global Real-World Data Market Size for Market Access & Reimbursement/Coverage Decisions, By Country/Region, 2024-2036 (USD Million)
  • Table 26. Global Real-World Data Market Size for Drug Development & Approvals, By Country/Region, 2024-2036 (USD Million)
  • Table 27. Key Global Post-Market Surveillance Infrastructure Using RWD (2025)
  • Table 28. Global Real-World Data Market Size for Post Market Surveillance, By Country/Region, 2024-2036 (USD Million)
  • Table 29. Global Real-World Data Market Size for Medical Device Development & Approvals, By Country/Region, 2024-2036 (USD Million)
  • Table 30. Global Real-World Data Market Size for Clinical & Regulatory Decision-Making, By Country/Region, 2024-2036 (USD Million)
  • Table 31. Key Global Real-World Data Market By End User - Overview (2026)
  • Table 32. Global Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 33. Global Pharmaceutical R&D Spending and RWD Context, 2019-2025p
  • Table 34. Global Real-World Data Market Size for Pharmaceutical & Medical Device Companies, By Country/Region, 2024-2036 (USD Million)
  • Table 35. Major Healthcare Payer Segments - RWD Use and Policy Context (2025-2026)
  • Table 36. Global Real-World Data Market Size for Healthcare Payers, By Country/Region, 2024-2036 (USD Million)
  • Table 37. Healthcare Provider Rwd Use Cases and Value Drivers (2025)
  • Table 38. Global Real-World Data Market Size for Healthcare Providers, By Country/Region, 2024-2036 (USD Million)
  • Table 39. Global Real-World Data Market Size for Other End Users, By Country/Region, 2024-2036 (USD Million)
  • Table 40. North America: Real-World Data Market Size, By Country, 2024-2036 (USD Million)
  • Table 41. North America: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 42. North America: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 43. North America: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 44. U.S.: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 45. U.S.: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 46. U.S.: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 47. Canada: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 48. Canada: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 49. Canada: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 50. Europe: Real-World Data Market, By Country, 2024-2036 (USD Million)
  • Table 51. Europe: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 52. Europe: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 53. Europe: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 54. Germany: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 55. Germany: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 56. Germany: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 57. U.K.: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 58. U.K.: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 59. U.K.: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 60. France: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 61. France: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 62. France: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 63. Italy: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 64. Italy: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 65. Italy: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 66. Spain: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 67. Spain: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 68. Spain: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 69. Rest of Europe: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 70. Rest of Europe: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 71. Rest of Europe: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 72. Asia-Pacific: Real-World Data Market Size, By Country, 2024-2036 (USD Million)
  • Table 73. Asia-Pacific: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 74. Asia-Pacific: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 75. Asia-Pacific: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 76. China: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 77. China: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 78. China: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 79. Japan: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 80. Japan: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 81. Japan: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 82. India: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 83. India: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 84. India: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 85. Rest of Asia-Pacific: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 86. Rest of Asia-Pacific: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 87. Rest of Asia-Pacific: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 88. Latin America - RWD/RWE Frameworks, By Country
  • Table 89. Latin America: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 90. Latin America: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 91. Latin America: Real-World Data Market Size, By End User, 2024-2036 (USD Million)
  • Table 92. Middle East and Africa: Real-World Data Market Size, By Source, 2024-2036 (USD Million)
  • Table 93. Middle East and Africa: Real-World Data Market Size, By Application, 2024-2036 (USD Million)
  • Table 94. Middle East and Africa: Real-World Data Market Size, By End User, 2024-2036 (USD Million)

LIST OF FIGURES

LIST OF FIGURES

  • Figure 1. Research Process
  • Figure 2. Key Secondary Sources
  • Figure 3. Primary Research Techniques
  • Figure 4. Key Executives Interviewed
  • Figure 5. Breakdown of Primary Interviews (Supply-Side & Demand-Side)
  • Figure 6. Market Sizing and Growth Forecast Approach
  • Figure 7. Global Rwd Market, By Source, 2026 Vs. 2036 (USD Million)
  • Figure 8. Global Rwd Market, By Application, 2026 Vs. 2036 (USD Million)
  • Figure 9. Global Rwd Market, By End User, 2025 Vs. 2036 (USD Million)
  • Figure 10. Rwd Market, By Geography, 2026 Vs 2036 (USD Million)
  • Figure 11. Global Real-World Data Market, By Source, 2025 Vs. 2036 (USD Million)
  • Figure 12. Global Real-World Data Market, By Application, 2026 Vs. 2036 (USD Million)
  • Figure 13. Global Real-World Data Market, By End User, 2026 Vs. 2036 (USD Million)
  • Figure 14. Global Real-World Data Market, By Region, 2026 Vs. 2036 (USD Million)
  • Figure 15. North America: Real-World Data Market Snapshot
  • Figure 16. Europe: Real-World Data Market Snapshot
  • Figure 17. Asia-Pacific: Real-World Data Market Snapshot
  • Figure 18. Rwd: Competitive Benchmarking, By Region
  • Figure 19. Competitive Dashboard: Rwd Market
  • Figure 20. Rwd Market Position Analysis, 2025
  • Figure 21. Iqvia Holdings Inc.: Financial Overview (2025)
  • Figure 22. Ppd Inc.: Financial Overview (2025)
  • Figure 23. Unitedhealth Group Incorporated: Financial Overview (2024)
  • Figure 24. Icon Plc.: Financial Overview (2024)
  • Figure 25. Oracle Corporation: Financial Overview (2025)
  • Figure 26. Elevance Health, Inc.: Financial Overview (2025)